Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PH$884.17-25.32(-2.78%)Parker-Hannifin Corporation (PH) Q1 2027 Earnings Call Transcript7:34:40 PM ETAAPL$343.68-5.88(-1.68%)Can Companies Stop Their Shares From Being Tokenized? Many Big Names Say Yes7:33:37 PM ETABNB$188.94+12.57(+7.13%)Airbnb Q3 Earnings Call Highlights7:15:30 PM ETNVDA$184.61+3.01(+1.66%)Nvidia Stock Just Crashed 22%. Jim Cramer Says It's the Cheapest in a Decade7:09:51 PM ETABNB$188.94+12.57(+7.13%)Airbnb Is Growing Again—and Even It's Surprised7:09:00 PM ETBX$119.50-6.08(-4.84%)MEDIA-Blackstone doubles lock-up periods for some Asian investors - FT7:06:27 PM ETMU$684.99-110.47(-13.89%)High Bandwidth Memory Market Outlook 2032: USD 15.99 Billion Valuation Driven by Advancements in Semiconductor Packaging | Mordor Intelligence7:00:00 PM ETJNJ$271.29-5.09(-1.84%)UPDATE 2-FDA grants J&J accelerated approval for head and neck cancer treatment6:53:59 PM ETNET$281.86+37.35(+15.28%)Cloudflare's stock mounts a big comeback after fastest sales surge in nearly 4 years6:50:00 PM ETPLTR$155.39-16.35(-9.52%)Palantir Is Down 16% From Its High. History Suggests This Is What Happens Next.6:45:00 PM ETNVDA$184.61+3.01(+1.66%)House G.O.P. Leaders Ask Nvidia's Huang to Speak in Closed-Door Briefing6:39:27 PM ETSNDK$842.00-195.18(-18.82%)Sandisk: This Is A Golden Opportunity6:18:30 PM ETPNC$226.750.00(0.00%)UPDATE 1-PNC names Alexander Overstrom as CFO, succeeding Robert Reilly6:11:49 PM ETAMD$419.00-69.69(-14.26%)Cathie Wood Just Sold AMD Stock and Bought This AI Chip Stock Instead6:00:00 PM ETBN$41.50-0.26(-0.62%)Brookfield Infrastructure Announces Update on Simplification5:50:00 PM ETVOYA-PB$23.360.00(0.00%)Corporate Insight Releases Research Series on AI Leaders in Financial Services5:48:25 PM ETJNJ$271.29-5.09(-1.84%)UPDATE 1-FDA grants J&J accelerated approval for head and neck cancer treatment5:47:37 PM ETCI$301.48-3.91(-1.28%)The Cigna Group (CI) Q3 2026 Earnings Call Transcript5:44:34 PM ETJNJ$271.29-5.09(-1.84%)FDA grants J&J accelerated approval for head and neck cancer treatment5:43:49 PM ETABNB$188.94+12.57(+7.13%)Airbnb says it's launching an AI travel agent in the first half of 20275:40:55 PM ETEOG$144.890.00(0.00%)UPDATE 3-US shale producer EOG Resources beats profit estimates on higher crude prices5:40:05 PM ETAMZN$259.15-7.04(-2.64%)Stock Market Today, Nov. 5: Amazon Shares Slide as Technology Selloff Erases Early Gains5:39:37 PM ETCNQ$49.06+0.14(+0.29%)Canadian Natural: Strong Results, 10%+ Yield5:39:28 PM ETSMCI$27.57-2.02(-6.83%)Super Micro: Major Plot Twist5:32:31 PM ET

ALLO · NASDAQ

Allogene Therapeutics, Inc.

$1.07 -0.12 (-10.08%)

Company overview

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for treating pediatric and adult patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia. It also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate in Phase I clinical trial for relapsed or refractory non-Hodgkin lymphoma; ALLO-501A in Phase I/II for relapsed or refractory large B-cell lymphoma or transformed follicular lymphoma; ALLO-715 in Phase I for relapsed or refractory multiple myeloma; ALLO-605 for multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 for renal cell cancer; ALLO-819 for acute myeloid…

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$370M
Employees
226
Headquarters
South San Francisco, CA
Website
allogene.com
CEO
David D. Chang
Listed
October 11, 2018
P/E
-1.39
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$37.1M
Operating income
-$190M
EBITDA
-$168M
Net income
-$174M
EPS
-$0.77
Total assets
$396M
Total debt
$81.1M
Earnings yield
-71.96%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

1.021.371.732.092.44
ALLO 1D NASDAQ O1.16H1.20L1.12C1.19+0.07 (+6.25%)Vol16.53M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics Q3 Earnings Call Highlights MarketBeat
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces Participation in Upcoming Investor Conferences GlobeNewswire
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Zacks Investment Research
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces Participation in September Investor Conference GlobeNewswire
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics, Inc. $ALLO Shares Acquired by Bank of America Corp DE Defense World
ALLOAllogene Therapeutics, Inc. Stock news Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs Zacks Investment Research
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics, Inc. $ALLO Shares Bought by Dimensional Fund Advisors LP Defense World
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript Seeking Alpha
ALLOAllogene Therapeutics, Inc. Stock news Allogene Therapeutics Q2 Earnings Call Highlights MarketBeat
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update GlobeNewswire
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors GlobeNewswire
ALLOAllogene Therapeutics, Inc. Stock news Kyverna Therapeutics Sinks 13%: Here's Why 24/7 Wall Street
ALLOAllogene Therapeutics, Inc. Press release Allogene Therapeutics Announces Planned CEO Succession GlobeNewswire
See more
FAQ

Questions about Allogene Therapeutics, Inc.

What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for treating pediatric and adult patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia. It also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate in Phase I clinical trial for relapsed or refractory non-Hodgkin lymphoma; ALLO-501A in Phase I/II for relapsed or refractory large B-cell lymphoma or transformed follicular lymphoma; ALLO-715 in Phase I for relapsed or refractory multiple myeloma; ALLO-605 for multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 for renal cell cancer; ALLO-819 for acute myeloid…
What is ALLO's market cap?
Allogene Therapeutics, Inc. (ALLO) is a listed stock with a live quote. The latest market cap on this page is $370M.
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. is headquartered in South San Francisco, CA.
How do I get ALLO news from the API?
Call GET /v1/news?tickers=ALLO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ALLO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALLO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ALLO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs